ATRX and central nervous system cancer: To delineate the extent to which tumor cell-autonomous and immune microenvironmental factors impaired in vivo growth of our ATRX-deficient glioma models, we compared survival among mice carrying AtrxWT or Atrx KO-A tumors in either the nude background, which lacks cellular immunity, or the C57BL/6 immune-intact background for our CT2A model.